» Articles » PMID: 12446280

Electric Currents Applied During Refractory Period Enhance Contractility and Systolic Calcium in the Ferret Heart

Overview
Date 2002 Nov 26
PMID 12446280
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

We investigated the mechanism of positive inotropism of electric currents applied during the absolute refractory period. Ten Langendorff-perfused ferret hearts were instrumented to measure isovolumic left ventricular pressure (LVP) and the aequorin luminescence. Biphasic square-wave electric currents (+/-20 mA, total duration 30 ms) were delivered between pairs of electrodes. Six hearts were perfused at different extracellular Ca(2+) concentrations ([Ca(2+)](o); 1, 2, 4, and 8 mM). These signals increased LVP from 50.0 +/- 9.4 to 70.1 +/- 14.7, from 67.5 +/- 11.0 to 79.0 +/- 15.6, from 79.3 +/- 21.0 to 87.1 +/- 22.8, and from 84.6 +/- 24.0 to 91.8 +/- 28.5 mmHg at the respective [Ca(2+)](o) (P < 0.05). Peak free intracellular [Ca(2+)] ([Ca(2+)](i)) increased from 0.52 +/- 0.13 to 1.37 +/- 0.23, from 0.76 +/- 0.23 to 1.73 +/- 0.14, from 1.10 +/- 0.24 to 2.05 +/- 0.33, and from 1.41 +/- 0.36 to 2.24 +/- 0.36 microM/ml, respectively (P < 0.001). With the use of 1 mg/l propranolol with 1 mM [Ca(2+)](o), LVP and [Ca(2+)](i) were increased significantly from 48.7 +/- 8.18 to 56.3 +/- 6.11 mmHg and from 0.61 +/- 0.11 to 1.17 +/- 0.20 microM, respectively (P < 0.05). In conclusion, positive inotropism of such electrical currents was due to increased peak [Ca(2+)](i) and Ca(2+) responsiveness of the myofilaments did not change significantly.

Citing Articles

Device-therapy in chronic heart failure: Cardiac contractility modulation versus cardiac resynchronization therapy.

Yuecel G, Gaasch L, Kodeih A, Hetjens S, Yazdani B, Pfleger S ESC Heart Fail. 2024; 12(1):456-466.

PMID: 39344273 PMC: 11769612. DOI: 10.1002/ehf2.15067.


Medical Management and Device-Based Therapies in Chronic Heart Failure.

Nguyen A, Hurwitz M, Abraham J, Blumer V, Flanagan M, Garan A J Soc Cardiovasc Angiogr Interv. 2024; 2(6Part B):101206.

PMID: 39131076 PMC: 11308856. DOI: 10.1016/j.jscai.2023.101206.


Cardiac Contractility Modulation for Heart Failure: Current and Future Directions.

Pipilas D, Hanley A, Singh J, Mela T J Soc Cardiovasc Angiogr Interv. 2024; 2(6Part B):101176.

PMID: 39131075 PMC: 11307863. DOI: 10.1016/j.jscai.2023.101176.


Cardiac contractility modulation: an effective treatment strategy for heart failure beyond reduced left ventricular ejection fraction?.

Riccardi M, Sammartino A, Adamo M, Inciardi R, Lombardi C, Pugliese N Heart Fail Rev. 2023; 28(5):1141-1149.

PMID: 37198505 DOI: 10.1007/s10741-023-10315-4.


Acute effects of cardiac contractility modulation stimulation in conventional 2D and 3D human induced pluripotent stem cell-derived cardiomyocyte models.

Feaster T, Feric N, Pallotta I, Narkar A, Casciola M, Graziano M Front Physiol. 2022; 13:1023563.

PMID: 36439258 PMC: 9686332. DOI: 10.3389/fphys.2022.1023563.